Aeglea BioTherapeutics (NASDAQ:AGLE) Lifted to “Hold” at StockNews.com

StockNews.com upgraded shares of Aeglea BioTherapeutics (NASDAQ:AGLE) from a sell rating to a hold rating in a research report released on Saturday.

Other research analysts have also issued reports about the company. Stifel Nicolaus started coverage on Aeglea BioTherapeutics in a report on Tuesday, July 25th. They set a buy rating and a $22.50 target price on the stock. Wells Fargo & Company raised their price target on shares of Aeglea BioTherapeutics from $8.75 to $12.50 and gave the company an equal weight rating in a research report on Wednesday, August 16th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $24.38.

Aeglea BioTherapeutics Stock Performance

NASDAQ:AGLE opened at $12.52 on Friday. Aeglea BioTherapeutics has a 1 year low of $2.66 and a 1 year high of $39.00. The stock has a market capitalization of $50.71 million, a price-to-earnings ratio of -0.18 and a beta of 2.53. The stock has a fifty day moving average price of $13.67 and a two-hundred day moving average price of $8.74.

Aeglea BioTherapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($41.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.50) by ($37.00). The business had revenue of $0.69 million for the quarter. Aeglea BioTherapeutics had a negative return on equity of 132.05% and a negative net margin of 22,195.36%. On average, analysts predict that Aeglea BioTherapeutics will post -3.34 EPS for the current year.

Institutional Investors Weigh In On Aeglea BioTherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. ExodusPoint Capital Management LP acquired a new stake in shares of Aeglea BioTherapeutics in the fourth quarter valued at about $47,000. Carlyle Group Inc. acquired a new position in shares of Aeglea BioTherapeutics during the 1st quarter worth $69,000. Two Sigma Investments LP grew its stake in Aeglea BioTherapeutics by 280.0% in the 4th quarter. Two Sigma Investments LP now owns 393,638 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 290,049 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Aeglea BioTherapeutics by 117.0% in the 2nd quarter. Renaissance Technologies LLC now owns 393,000 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 211,900 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its holdings in Aeglea BioTherapeutics by 46.6% in the first quarter. Sphera Funds Management LTD. now owns 646,478 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 205,641 shares during the period.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.